$XERI
XERIANT, INC. Stock $xeri

$xeri Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000147793222003485 Filed on May 16, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.369M	$825.3K	$1.167M
YoY Change	256.79%	481.61%	9.61%
% of Gross Profit
Research & Development	$59.78K	$7.587K	$2.860M
YoY Change	-83.98%
% of Gross Profit
Depreciation & Amortization	$15.25K	$250.00	$80.00
YoY Change
% of Gross Profit
Operating Expenses	$1.429M	$1.071M	$4.260M
YoY Change	88.81%	368.6%	280.11%
Operating Profit		-$1.071M	-$4.260M
YoY Change		368.6%	280.11%
Interest Expense	-$1.674M	$134.9K	$1.625K
YoY Change	1742.54%	4970.54%	42.67%
% of Operating Profit
Other Income/Expense, Net		-$1.734M	-$1.267M
YoY Change		1537.24%	1643.76%
Pretax Income	-$3.103M	-$2.805M	-$5.526M
YoY Change	266.05%	738.61%	363.11%
Income Tax
% Of Pretax Income
Net Earnings	-$3.745M	-$2.805M	-$5.526M
YoY Change	493.38%	738.6%	363.11%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$10.36K	-$7.709K	-$9.891K
COMMON SHARES
Basic Shares Outstanding	365.2M shares	364.3M shares	322.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.124M	$1.694M	$2.111M
YoY Change	16.73%	12.41%	10646.18%
Cash & Equivalents	$1.066M	$1.693M	$2.111M
Short-Term Investments	$57.68K
Other Short-Term Assets	$13.30K	$14.34K	$15.37K
YoY Change	-3.48%	-81.22%	12.85%
Inventory
Prepaid Expenses	$756.00	$1.790K	$2.823K
Receivables
Other Receivables
Total Short-Term Assets	$1.137M	$1.708M	$2.126M
YoY Change	16.45%	7.89%	6291.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.409K	$19.66K	$4.907K
YoY Change	-97.39%	-89.0%	-97.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$60.00K
YoY Change
Other Assets	$10.00K
YoY Change
Total Long-Term Assets	$132.8K	$158.6K	$154.2K
YoY Change	-21.55%	-11.28%	-18.02%
TOTAL ASSETS
Total Short-Term Assets	$1.137M	$1.708M	$2.126M
Total Long-Term Assets	$132.8K	$158.6K	$154.2K
Total Assets	$1.270M	$1.866M	$2.280M
YoY Change	10.84%	5.95%	929.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$56.84K	$33.96K	$23.74K
YoY Change	-22.37%	81.22%	-20.87%
Accrued Expenses	$70.96K	$30.00K	$30.00K
YoY Change	183.84%	-55.99%	-49.34%
Deferred Revenue
YoY Change
Short-Term Debt	$3.936M	$2.320M	$721.1K
YoY Change	2388.11%	2153.93%	3035.04%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.139M	$2.418M	$820.5K
YoY Change	1284.05%	1174.03%	652.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$92.20K	$117.6K	$117.6K
YoY Change	-34.68%	-22.83%	-28.0%
Total Long-Term Liabilities	$92.20K	$117.6K	$117.6K
YoY Change	-34.68%	-22.83%	-28.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.139M	$2.418M	$820.5K
Total Long-Term Liabilities	$92.20K	$117.6K	$117.6K
Total Liabilities	$4.231M	$2.536M	$938.1K
YoY Change	861.19%	641.11%	244.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.57M	-$12.83M	-$10.03M
YoY Change	406.74%
Common Stock	$3.637K	$3.633K	$3.577K
YoY Change	24.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$164.1K	-$669.6K	$1.342M
YoY Change
Total Liabilities & Shareholders Equity	$1.270M	$1.866M	$2.280M
YoY Change	10.84%	5.95%	929.96%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$3.745M	-$2.805M	-$5.526M
YoY Change	493.38%	738.6%	363.11%
Depreciation, Depletion And Amortization	$15.25K	$250.00	$80.00
YoY Change
Cash From Operating Activities	-$512.2K	-$402.1K	-$3.285M
YoY Change	-20.22%	93.65%	3701.5%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$15.00K	-$4.990K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$115.4K
YoY Change
Cash From Investing Activities	-$115.4K	-$15.00K	-$4.990K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	5.119M
YoY Change	-100.0%	-100.0%	7898.36%
NET CHANGE
Cash From Operating Activities	-512.2K	-402.1K	-3.285M
Cash From Investing Activities	-115.4K	-15.00K	-4.990K
Cash From Financing Activities	0.000	0.000	5.119M
Net Change In Cash	-627.5K	-417.1K	1.829M
YoY Change	15.35%	-128.05%	-8256.56%
FREE CASH FLOW
Cash From Operating Activities	-$512.2K	-$402.1K	-$3.285M
Capital Expenditures	$0.00	-$15.00K	-$4.990K
Free Cash Flow	-$512.2K	-$387.1K	-$3.280M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	365239001	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1693495	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	962540	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33962	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25000	USD
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2319738	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	3633	USD
CY2022Q1	us-gaap	Minority Interest MinorityInterest	-3438980	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2418485	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	2925	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	299063	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117585	USD
CY2022Q1	xeri	Common Stock To Be Issued CommonStockToBeIssued	97900	shares
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	158196	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	34785	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	42643	USD
CY2021Q2	us-gaap	Minority Interest MinorityInterest	-216686	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	141160	USD
CY2022Q1	us-gaap	Liabilities Liabilities	2536070	USD
CY2021Q2	us-gaap	Liabilities Liabilities	440223	USD
CY2022Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	292815960	shares
CY2021Q2	xeri	Common Stock To Be Issued CommonStockToBeIssued	51090	shares
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	15494788	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4138194	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12826977	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3270235	USD
CY2022Q1	xeri	Controlling Interest ControllingInterest	2769362	USD
CY2021Q2	xeri	Controlling Interest ControllingInterest	921992	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1866452	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1145529	USD
CY2022Q1	us-gaap	Marketing Expense MarketingExpense	25771	USD
CY2021Q1	us-gaap	Marketing Expense MarketingExpense	0	USD
	us-gaap	Marketing Expense MarketingExpense	670989	USD
	us-gaap	Marketing Expense MarketingExpense	1000000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	799521	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	141897	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3120772	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	242445	USD
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	102646	USD
CY2021Q1	us-gaap	Professional Fees ProfessionalFees	32160	USD
	us-gaap	Professional Fees ProfessionalFees	234671	USD
	us-gaap	Professional Fees ProfessionalFees	67397	USD
CY2022Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	135500	USD
CY2021Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	54500	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	348925	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	132500	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7587	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5207806	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1071025	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	228557	USD
	us-gaap	Operating Expenses OperatingExpenses	9583163	USD
	us-gaap	Operating Expenses OperatingExpenses	1442342	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1071025	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-228557	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9583163	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1442342	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1598683	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	103225	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3012642	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	215635	USD
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
CY2021Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
CY2022Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-536	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-186954	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1733613	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-105886	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3195869	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	122688	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	5000	USD
CY2022Q1	us-gaap	Legal Fees LegalFees	0	USD
CY2021Q1	us-gaap	Legal Fees LegalFees	0	USD
	us-gaap	Legal Fees LegalFees	43750	USD
	us-gaap	Legal Fees LegalFees	0	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	134927	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	2661	USD
	us-gaap	Interest Expense InterestExpense	138941	USD
	us-gaap	Interest Expense InterestExpense	4857	USD
CY2021Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	76	USD
CY2022Q1	xeri	Gain On Forgiveness Of Accounts Payable GainOnForgivenessOfAccountsPayable	0	USD
CY2021Q1	xeri	Gain On Forgiveness Of Accounts Payable GainOnForgivenessOfAccountsPayable	0	USD
	xeri	Gain On Forgiveness Of Accounts Payable GainOnForgivenessOfAccountsPayable	0	USD
	xeri	Gain On Forgiveness Of Accounts Payable GainOnForgivenessOfAccountsPayable	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-412522	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7425	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	0	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3222294	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	0	USD
CY2022Q1	xeri	Common Stockholders CommonStockholders	-2797213	USD
CY2021Q1	xeri	Common Stockholders CommonStockholders	0	USD
	xeri	Common Stockholders CommonStockholders	-9556738	USD
	xeri	Common Stockholders CommonStockholders	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2804638	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-334443	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12779032	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1854864	USD
CY2022Q1	xeri	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.01
CY2021Q1	xeri	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.00
	xeri	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.04
	xeri	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.01
CY2022Q1	xeri	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	362872609	shares
CY2021Q1	xeri	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	234451953	shares
	xeri	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	339759839	shares
	xeri	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	176685459	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	705306	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1668500	USD
CY2021Q3	xeri	Shares Issued As Equity Kicker Amount SharesIssuedAsEquityKickerAmount	43753	USD
CY2021Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	128550	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	173070	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	541100	USD
CY2021Q3	xeri	Adjustments To Additional Paid In Capital Tax Effects From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectsFromShareBasedCompensation	1060324	USD
CY2021Q3	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	250000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-4447915	USD
CY2022Q1	xeri	Issuance Of Common Stock Committed In Prior Period Amount IssuanceOfCommonStockCommittedInPriorPeriodAmount	3749	USD
CY2022Q1	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	USD
CY2022Q1	xeri	Inducement Of Conversion Interest Expense Amount InducementOfConversionInterestExpenseAmount	134927	USD
CY2022Q1	xeri	Stock Option Compensation Amount StockOptionCompensationAmount	574563	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	79750	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-2804638	USD
CY2021Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	410000	USD
CY2021Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021Q4	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-669618	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-31224	USD
CY2021Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	250000	USD
CY2021Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	116104	USD
CY2021Q4	xeri	Adjustments To Additional Paid In Capital Tax Effects From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectsFromShareBasedCompensation	827221	USD
CY2021Q4	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	2777081	USD
CY2021Q4	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	2365419	USD
CY2021Q4	us-gaap	Profit Loss ProfitLoss	-5526483	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1342031	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	51145	USD
CY2020Q3	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	36407	USD
CY2020Q3	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	42893	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	200454	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-327072	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-27397	USD
CY2020Q3	xeri	Shares Reclassed From Common Stock To Be Issued Amount SharesReclassedFromCommonStockToBeIssuedAmount	0	USD
CY2020Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	51000	USD
CY2020Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	78714	USD
CY2020Q3	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	USD
CY2020Q4	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	6388	USD
CY2020Q4	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	6612	USD
CY2020Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1013200	USD
CY2020Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	13909	USD
CY2020Q4	us-gaap	Profit Loss ProfitLoss	-1193349	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-50923	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1497000	USD
CY2021Q1	xeri	Shares Reclassed From Common Stock To Be Issued Amount SharesReclassedFromCommonStockToBeIssuedAmount	-4	USD
CY2021Q1	xeri	Conversion Of Convertible Notes And Accrued Interest Shares ConversionOfConvertibleNotesAndAccruedInterestShares	23856	shares
CY2021Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	75097	USD
CY2021Q1	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	122453	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	62050	USD
CY2021Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	24422	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-344596	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1409355	USD
	us-gaap	Profit Loss ProfitLoss	-12779032	USD
	us-gaap	Profit Loss ProfitLoss	-1854864	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	332	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2462108	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1113583	USD
	xeri	Stock Issued For Services StockIssuedForServices	736954	shares
	xeri	Financing Fees FinancingFees	178676	USD
	xeri	Financing Fees FinancingFees	0	USD
	xeri	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	0	USD
	xeri	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	186954	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3012642	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	215635	USD
	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	0	USD
	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	5000	USD
	xeri	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	30246	USD
	xeri	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	93	USD
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-31433	USD
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	0	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-556	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-62458	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-35513	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	25880	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	5000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5520	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6415055	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-370177	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19990	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19990	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2078500	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1548000	USD
	xeri	Cash From Exercise Of Warrants CashFromExerciseOfWarrants	128550	USD
	xeri	Cash From Exercise Of Warrants CashFromExerciseOfWarrants	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4958950	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	289850	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7166000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1837850	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	730955	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1467673	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	962540	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38893	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1693495	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1506566	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	440995	USD
	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	130410	USD
	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	2894974	USD
	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	117892	USD
	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	2787376	USD
	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	171958	USD
	xeri	Income Tax Positions Percentage Description IncomeTaxPositionsPercentageDescription	greater than 50%
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.</p>
	xeri	Going Concern Policytextblock GoingConcernPolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At March 31, 2022 and June 30, 2021, the Company had $1,693,495 and $962,540 in cash and $(710,654) and $677,257 in working capital, respectively. For the nine months ended March 31, 2022 and 2021, the Company had a net loss of $12,779,032 and $1,854,864, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems.</p>
CY2022Q1	us-gaap	Cash Cash	1693495	USD
CY2021Q2	us-gaap	Cash Cash	962540	USD
CY2022Q1	xeri	Working Capital WorkingCapital	-710654	USD
CY2021Q2	xeri	Working Capital WorkingCapital	677257	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12779032	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1854864	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7587	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5207806	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	3690	USD
CY2021Q1	us-gaap	Advertising Expense AdvertisingExpense	0	USD
	us-gaap	Advertising Expense AdvertisingExpense	168403	USD
	us-gaap	Advertising Expense AdvertisingExpense	0	USD
	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	1443495	USD
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.10	pure
CY2022Q1	us-gaap	Prepaid Rent PrepaidRent	4659	USD
CY2022Q1	xeri	Right Of Use Asset Office Lease RightOfUseAssetOfficeLease	220448	USD
CY2022Q1	xeri	Right Of Use Asset Accumulated Amortization RightOfUseAssetAccumulatedAmortization	-81485	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	138963	USD
	xeri	Summary Of Operating Lease Liabilitypolicytextblock SummaryOfOperatingLeaseLiabilitypolicytextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Office lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,370</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(34,785 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">117,585</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q1	xeri	Office Leas OfficeLeas	152370	USD
CY2022Q1	xeri	Operating Lease Liability Current Portion OperatingLeaseLiabilityCurrentPortion	-34785	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117585	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14804	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	60392	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	62201	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	37112	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	174508	USD
CY2022Q1	xeri	Present Value Discount PresentValueDiscount	-22138	USD
CY2022Q1	xeri	Office Leas OfficeLeas	152370	USD
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2319738	USD
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	158196	USD
CY2022Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	6050000	USD
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	167550	USD
CY2022Q1	xeri	Less Unamortized Discount LessUnamortizedDiscount	-3730262	USD
CY2021Q2	xeri	Less Unamortized Discount LessUnamortizedDiscount	-9354	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2319738	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	158196	USD
CY2020Q4	us-gaap	Interest Expense Other InterestExpenseOther	892300	USD
CY2020Q4	us-gaap	Professional Fees ProfessionalFees	342950	USD
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	167550	USD
CY2021Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	6050000	USD
CY2021Q4	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	5142500	USD
CY2021Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	907500	USD
CY2021Q4	us-gaap	Professional Fees ProfessionalFees	433550	USD
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.1187
CY2021Q4	xeri	Offering Price Per Share OfferingPricePerShare	0.75	pure
CY2021Q4	xeri	Aggregate Warrant Issued Of Common Stock AggregateWarrantIssuedOfCommonStock	50968828	shares
CY2021Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2777081	USD
CY2022Q1	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt Additional Paid In Capital FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebtAdditionalPaidInCapital	2365419	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3730262	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3012642	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	215635	USD
	us-gaap	Interest Expense Other InterestExpenseOther	4014	USD
	us-gaap	Interest Expense Other InterestExpenseOther	2196	USD
	xeri	Debt Instrument Convertible Beneficial Conversion Feature For Future DebtInstrumentConvertibleBeneficialConversionFeatureForFuture	2539	USD
	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	0	USD
	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	5000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	76	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2021Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	363778386	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	292815960	shares
CY2021Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4185000	shares
CY2021Q3	xeri	Proceeds From Warrants Exercises ProceedsFromWarrantsExercises	125550	USD
CY2021Q3	xeri	Common Stock Issued For Prior Period Conversions Principal And Interest CommonStockIssuedForPriorPeriodConversionsPrincipalAndInterest	10598544	shares
CY2021Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	167550	USD
CY2021Q3	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	4985	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	535	USD
CY2022Q1	xeri	Common Stock Issued For Prior Period Conversions Principal And Interest CommonStockIssuedForPriorPeriodConversionsPrincipalAndInterest	4229680	shares
CY2022Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	250000	USD
CY2022Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3749	USD
CY2022Q1	xeri	Additional Common Shares Issued As Financing Costs AdditionalCommonSharesIssuedAsFinancingCosts	845936	shares
CY2022Q1	xeri	Inducment Of Conversion Interest Expense Amount InducmentOfConversionInterestExpenseAmount	134927	USD
CY2021Q3	us-gaap	Share Price SharePrice	0.03
CY2021Q3	xeri	Common Stock Shares Issued In Exchange For Services Value CommonStockSharesIssuedInExchangeForServicesValue	46400	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	19000000	shares
CY2021Q3	us-gaap	Share Price SharePrice	0.12
CY2022Q1	xeri	Fair Value Of Stock Option FairValueOfStockOption	3543787	USD
CY2022Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2462108	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1125008	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4750000	shares
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y3M21D
	xeri	Outstanding Beginning Aggregate Intrinsic Value OutstandingBeginningAggregateIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	19000000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.12
	xeri	Outstanding At Ending OutstandingAtEnding	P2Y3M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	4750000	shares
	xeri	Impact Of Restatement On Earnings Per Shares Diluted ImpactOfRestatementOnEarningsPerSharesDiluted	0.12
	xeri	Sharebased Compensation Arrangement By Sharebased Payment Grant In Period SharebasedCompensationArrangementBySharebasedPaymentGrantInPeriod	P2Y3M18D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4750000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.12
	xeri	Exercisable At End Of Year ExercisableAtEndOfYear	P2Y3M18D
	xeri	Summary Of Stock Warrants Activity Tabletextblock SummaryOfStockWarrantsActivityTabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Options (in thousands)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted-</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted-</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average Contractual Term</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(in years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,848,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.03</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.94</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,968,828</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.1187</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,305,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Canceled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,512,161</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.111</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.3</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested and expected to vest at March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,512,161</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.111</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.3</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercisable at March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,512,161</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.111</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.3</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>

Files In Submission

Name	View Source	Status
0001477932-22-003485-index-headers.html	Edgar Link	pending
0001477932-22-003485-index.html	Edgar Link	pending
0001477932-22-003485.txt	Edgar Link	pending
0001477932-22-003485-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeri-20220331.xsd	Edgar Link	pending
xeri-20220331_cal.xml	Edgar Link	unprocessable
xeri-20220331_def.xml	Edgar Link	unprocessable
xeri-20220331_lab.xml	Edgar Link	unprocessable
xeri-20220331_pre.xml	Edgar Link	unprocessable
xeri_10q.htm	Edgar Link	pending
xeri_10q_htm.xml	Edgar Link	completed
xeri_ex101.htm	Edgar Link	pending
xeri_ex102.htm	Edgar Link	pending
xeri_ex103.htm	Edgar Link	pending
xeri_ex311.htm	Edgar Link	pending
xeri_ex312.htm	Edgar Link	pending
xeri_ex321.htm	Edgar Link	pending
xeri_ex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERI
XERIANT, INC. Stock $xeri

2022 Q2 Form 10-Q Financial Statement

#000147793222003485 Filed on May 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI XERIANT, INC. Stock $xeri

2022 Q2 Form 10-Q Financial Statement

#000147793222003485 Filed on May 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI
XERIANT, INC. Stock $xeri